Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03312595 · ClinicalTrials.gov registry record · NA

Clinical Outcomes After Treatment With RestrataTM Wound Matrix in Diabetic Foot Ulcers (DFU)

A NA study, sponsored by Acera Surgical.

Completed
Registry status
NA
Development phase
30
Enrollment target

NCT03312595 is a NA study that has completed, run by Acera Surgical. The registered enrollment target is 30 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03312595, a NA study, has completed, sponsored by Acera Surgical.

COMPLETED
Registry status
NA
Development phase
30 participants
Enrollment target

Study Summary

The primary objective of this study is to determine the outcomes of patients who receive a certain type of skin substitute called RestrataTM Wound Matrix (Restrata™). Results of this study may be used to make decisions on whether to conduct additional studies on this particular wound matrix product. RestrataTM has been cleared by the Food and Drug Administration for use in certain types of ulcer treatments, including the type that will be part of this study (diabetic foot ulcers).

Interventions

  • DEVICE Restrata TM Wound Matrix

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2017-09-14
Est. Completion 2018-07-30
Phase NA

Sponsor

Acera Surgical

5 total trials

What the Registry Record Tells You About NCT03312595

The ClinicalTrials.gov registry entry for NCT03312595 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Acera Surgical, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Restrata TM Wound Matrix is the first listed.

NCT03312595 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03312595 about?

NCT03312595 is a clinical study titled "Clinical Outcomes After Treatment With RestrataTM Wound Matrix in Diabetic Foot Ulcers (DFU)". The primary objective of this study is to determine the outcomes of patients who receive a certain type of skin substitute called RestrataTM Wound Matrix (Restrata™). Results of this study may be used to make decisions on whether to conduct additional studies on this particular wound matrix product....

What is the current status of trial NCT03312595?

This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2017-09-14. Estimated completion is 2018-07-30.

What interventions are being tested in trial NCT03312595?

The interventions under investigation include: Restrata TM Wound Matrix (DEVICE).

Who is sponsoring clinical trial NCT03312595?

This trial is sponsored by Acera Surgical, which has 5 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.